| scholarly article | Q13442814 |
| P50 | author | Philip W. Kantoff | Q42532150 |
| Toni K Choueiri | Q88414622 | ||
| Sabina Signoretti | Q90424571 | ||
| P2093 | author name string | Matthew L Freedman | |
| Michael B Atkins | |||
| David F McDermott | |||
| Michelle S Hirsch | |||
| Jonathan E Rosenberg | |||
| Fabio A B Schutz | |||
| Kathryn P Gray | |||
| Mark M Pomerantz | |||
| Gwo-Shu Mary Lee | |||
| Megan E Lampron | |||
| P2860 | cites work | Vitamin D pathway gene variants and prostate cancer prognosis | Q24628345 |
| A second generation human haplotype map of over 3.1 million SNPs | Q24651939 | ||
| A genetic variant that disrupts MET transcription is associated with autism | Q24674115 | ||
| Statistical significance for genomewide studies | Q24681264 | ||
| Targeting the c-Met signaling pathway in cancer | Q28246393 | ||
| Invasive growth: a MET-driven genetic programme for cancer and stem cells | Q28253680 | ||
| Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3 | Q28943264 | ||
| Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis. | Q33267032 | ||
| Variants in blood pressure genes and the risk of renal cell carcinoma | Q33759665 | ||
| High quality and quantity Genome-wide germline genotypes from FFPE normal tissue | Q33912977 | ||
| The genetic basis of kidney cancer: a metabolic disease | Q34087148 | ||
| New insights into the biology of renal cell carcinoma | Q35180400 | ||
| Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. | Q35619699 | ||
| The chromosome 2p21 region harbors a complex genetic architecture for association with risk for renal cell carcinoma | Q35750240 | ||
| Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy | Q36718954 | ||
| Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer | Q36974142 | ||
| Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality | Q37262639 | ||
| Novel therapeutic inhibitors of the c-Met signaling pathway in cancer | Q37422804 | ||
| Apolipoprotein E/C1 locus variants modify renal cell carcinoma risk | Q37474966 | ||
| Germline genetic variation, cancer outcome, and pharmacogenetics | Q37777288 | ||
| Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression. | Q39382008 | ||
| Association of matrix metalloproteinase-8 gene variation with breast cancer prognosis | Q40059308 | ||
| Several methods to assess improvement in risk prediction models: Extension to survival analysis | Q44667332 | ||
| Impact of interleukin-10 polymorphisms (-1082 and -3575) on the survival of patients with lymphoid neoplasms | Q44996190 | ||
| Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas | Q45345804 | ||
| Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. | Q46005386 | ||
| Renal-cell carcinoma--molecular pathways and therapies. | Q55042930 | ||
| Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors | Q74381357 | ||
| Low predictive accuracy of the Kattan postoperative nomogram for renal cell carcinoma recurrence in a population of French patients | Q79318178 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | single-nucleotide polymorphism | Q501128 |
| P304 | page(s) | 81-87 | |
| P577 | publication date | 2012-12-07 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study | |
| P478 | volume | 14 |
| Q92690608 | A pan-cancer analysis of synonymous mutations |
| Q27852242 | Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network |
| Q91797590 | An analysis of mutational signatures of synonymous mutations across 15 cancer types |
| Q36327886 | Association Analysis of MET Gene Polymorphism with Papillary Thyroid Carcinoma in a Chinese Population. |
| Q36275134 | Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. |
| Q37573538 | Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression. |
| Q43806776 | Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. |
| Q85348536 | Clinical significance of tumor-derived IL-1β and IL-18 in localized renal cell carcinoma: Associations with recurrence and survival |
| Q38912279 | Development of antibody-based c-Met inhibitors for targeted cancer therapy |
| Q43866819 | Focused screening of a panel of cancer-related genetic polymorphisms reveals new susceptibility loci for pediatric acute lymphoblastic leukemia. |
| Q30009003 | Genetic Variation in the Human SORBS1 Gene is Associated With Blood Pressure Regulation and Age at Onset of Hypertension: A SAPPHIRe Cohort Study |
| Q34698356 | Genetic polymorphism of the kinesin-like protein KIF1B gene and the risk of hepatocellular carcinoma |
| Q95642983 | Germline Polymorphisms and Length of Survival of Nasopharyngeal Carcinoma: An Exome-Wide Association Study in Multiple Cohorts |
| Q41688195 | High APOBEC3B expression is a predictor of recurrence in patients with low-risk clear cell renal cell carcinoma |
| Q35788029 | High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes |
| Q41279859 | IRF5 is associated with adverse postoperative prognosis of patients with non-metastatic clear cell renal cell carcinoma |
| Q54760339 | Kidney cancer: Recurrence in renal cell carcinoma: the work is not done. |
| Q36116625 | Kinase Gene Expression Profiling of Metastatic Clear Cell Renal Cell Carcinoma Tissue Identifies Potential New Therapeutic Targets |
| Q38910995 | Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact |
| Q47123004 | Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma |
| Q38702306 | Potential protective role of Grainyhead-like genes in the development of clear cell renal cell carcinoma. |
| Q38163227 | Precision medicine for metastatic renal cell carcinoma |
| Q38970282 | Precision medicine from the renal cancer genome |
| Q38196855 | Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents |
| Q34446136 | Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients |
| Q48683198 | Selected news from the 2014 Genitourinary Cancers Symposium: translating novel strategies into clinical practice. |
| Q33975510 | The associations between immunity-related genes and breast cancer prognosis in Korean women |
| Q26753387 | The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations |
| Q38418649 | Tumour and patient factors in renal cell carcinoma-towards personalized therapy |
| Q38148602 | VEGF pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a 2013 update |
| Q36716606 | Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma |
| Q33563168 | Whole-genome analysis of papillary kidney cancer finds significant noncoding alterations |
| Q33886974 | c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer |
| Q86617608 | β1,6-N-acetylglucosaminyltransferase V predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection |
Search more.